Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors

US8318718B2 · kind B2 · utility

Assignee

• AMGEN INC. · US

Inventors

• Jennifer R. Allen · Newbury Park, US
• Biswas Kaustav · Craydon Court, US
• Frank Chavez · San Diego, US
• Ning Chen · Thousand Oaks, US
• Frenel F. De Morin · Thousand Oaks, US
• James R. Falsey · Moorpark, US
• Michael J. Frohn · Thousand Oaks, US
• Paul E. Harrington · Camarillo, US
• Daniel B. Horne · Natick, US
• Essa Hu Harrington · Camarillo, US
• Matthew R. Kaller · Ventura, US
• Roxanne Kunz · Santa Monica, US
• Holger Monenschein · San Diego, US
• Thomas Nguyen · Newbury Park, US
• Alexander J. Pickrell · Westlake Village, US
• Andreas Reichelt · Moorpark, US
• Shannon Rumfelt · Camarillo, US
• Robert M. Rzasa · Ventura, US
• Kelvin Sham · Thousand Oaks, US
• Guomin Yao · Mililani, US

Key dates

• Filing date: Nov 16, 2009
• Grant date: Nov 27, 2012
• Expiry date: Nov 27, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D473/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Pyridine and pyrimidine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.